Abstract
Abacavir use and myocardial infarction - Where are we now?
Highlights
The ongoing exposure of antiretrovirals of different classes and different side effect profiles have emerged with a variety of problems in the management of HIV infection
This observation has been contradicted by several other observational cohort studies and meta-analysis conducted by GSK that did not show any association of abacavir with myocardial infarction (MI) and cardiovascular disease [7,8]
The first study which created a lot of interest about abacavir use and the risk of cardiovascular disease (CVD) came from D:A:D cohort [3]
Summary
The ongoing exposure of antiretrovirals of different classes and different side effect profiles have emerged with a variety of problems in the management of HIV infection. The findings from D:A:D cohort suggested that use of abacavir was associated with an increased risk of MI both in terms of cumulative and recent exposure to the drug. The same group from the ANRS in France updated the results of their studies and these suggest that people with traditional cardiovascular risk factors were significantly more likely to receive either abacavir or tenofovir.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
